ZNF503 as a Radioligand Therapy Target
ZNF503, zinc finger protein 503, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, ZNF503 staining is highest in ovarian cancer (100% of samples positive), head and neck cancer (100% of samples positive) and prostate cancer (100% of samples positive). Clinical status: Discovery-stage (no clinical drug program).
Is ZNF503 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in ovarian cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
ZNF503 expression in cancer
Protein expression of ZNF503 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Ovarian Cancer | 0.69 | High | 100% |
| Head and Neck Cancer | 0.58 | High | 100% |
| Prostate Cancer | 0.57 | High | 100% |
| Skin Cancer | 0.56 | High | 92% |
| Bladder Cancer | 0.55 | High | 100% |
| Endometrial Cancer | 0.52 | High | 100% |
| Glioma | 0.50 | Medium | 100% |
| Breast Cancer | 0.47 | Medium | 100% |
| Kidney Cancer | 0.47 | Medium | 100% |
| Cervical Cancer | 0.47 | Medium | 100% |
| Colorectal Cancer | 0.46 | Medium | 100% |
| Pancreatic Cancer | 0.44 | Medium | 100% |
| Lung Cancer | 0.40 | Medium | 100% |
| Testicular Cancer | 0.39 | Medium | 100% |
| Gastric Cancer | 0.37 | Medium | 100% |
| Thyroid Cancer | 0.33 | Medium | 100% |
| Neuroendocrine Tumors | 0.33 | Medium | 100% |
| Lymphoma | 0.28 | Medium | 83% |
| Liver Cancer | 0.28 | Medium | 75% |
| Melanoma | 0.24 | Medium | 73% |
Is ZNF503 internalized?
Nuclens has not yet extracted internalization evidence for ZNF503. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
ZNF503 clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for ZNF503 yet. Search ClinicalTrials.gov for ZNF503 trials.
ZNF503 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See ZNF503 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
ZNF503 gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: 0.04 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related ovarian cancer radioligand targets
c-MET (MET) · HER3 (ERBB3) · Mesothelin (MSLN) · EPCAM · STEAP2 · FAP · ITGAV · EGFR
See all radioligand therapy targets in ovarian cancer.
See how ZNF503 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.